Human Papillomavirus Testing Compared With Cytology for Cervical Cancer Screening Among Women Living With HIV in the Dominican Republic.
Researchers
Margaret M Madeleine, Flavia Lantigua, Arismendy Benítez Abreu, Hoisex Gomez, Estefani Sánchez Marte, María Isabel Perez, Felix de Jesus Padilla Torres, Ernestina Hernández, Angélica Mondragón, Kelly Shrader, Margaret G House, Emma Brofsky, David R Doody, Miguelina Sánchez, Federica Inturrisi, César Rodriguez, Natalia Martinez, Carmen Soto, Martha Pérez Mencia, Robert Paulino-Ramirez, Lina José, Ydelsi Hernandez, Mariel Pacheco, Diego Guillen, Vikrant V Sahasrabuddhe, Silvia de Sanjosé, Yeycy Donastorg
Abstract
Women living with HIV (WWH) face elevated cervical cancer risk, yet evidence supporting primary human papillomavirus (HPV) testing in low-resource settings remains limited. We compared HPV testing with cytology for detection of cervical precancer among WWH in the Dominican Republic to inform national screening strategies. In this cross-sectional analysis from US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network Trial 302 (Estudio Oportunidad, ClinicalTrials.gov identifier: NCT05556772), 575 WWH contributed provider- and self-collected samples for cytology and HPV hierarchical testing. Women with positive results on cytology, provider-collected HPV testing, or self-collected HPV testing were referred for colposcopy and biopsy. Screening test characteristics were evaluated using centrally adjudicated histologic end points. Women with positive results on any screening test had higher HIV viral loads, lower CD4 counts, and were younger than women with screen-negative results. Sensitivity to detect cervical intraepithelial neoplasia grade 3 (CIN3+) by cytology (66.7% [95% CI, 49.2 to 80.5]) was lower than sensitivity of provider-collected results with either 13 high-risk HPV (hrHPV) genotypes (93.9 [95% CI, 78.7 to 98.5]) or 8 hrHPV genotypes (84.8% [95% CI, 68.3 to 98.6]). Self-collected samples had the highest sensitivity (97.0%, 95% CI, 81.3 to 99.6). Cytology missed 33.3% of CIN3+, hrHPV testing of provider-collected samples missed 6.1%-15.2% of CIN3+, and hrHPV testing of self-collected samples missed 3.0% of CIN3+. Among WWH in the Dominican Republic, HPV testing, whether provider- or self-collected, outperformed cytology for detection of CIN3+. Both 13- and 8-genotype hrHPV panels demonstrated high sensitivity but low specificity, resulting in high referral rates to colposcopy. These findings support transitioning to primary HPV-based screening for WWH in the Dominican Republic to increase accuracy in detecting precancer and reduce the cervical cancer burden among WWH.Source: PubMed (PMID: 43050623)View Original on PubMed